Skip to Content

Hyaluronidase / pertuzumab / trastuzumab Side Effects

Medically reviewed by Last updated on Aug 3, 2020.

For the Consumer

Applies to hyaluronidase/pertuzumab/trastuzumab: subcutaneous solution


This medicine can cause life-threatening heart or lung problems. Call your doctor at once if you have trouble breathing, swelling or rapid weight gain, fast or pounding heartbeats, or if you feel light-headed.

Do not use if you are pregnant. Use effective birth control during treatment and for at least 7 months after your last dose.

Get emergency medical help if you have signs of an allergic reaction: hives, rash; fever, chills, dizziness; nausea, vomiting, diarrhea; chest pain, difficult breathing; swelling of your face, lips, tongue, or throat.

This medicine can cause life-threatening heart or lung problems. Call your doctor at once if you have:

  • a new or worsening cough or shortness of breath (even while at rest);

  • fast or pounding heartbeats;

  • severe headache, blurred vision, pounding in your neck or ears;

  • swelling in your face or lower legs;

  • rapid weight gain (more than 5 pounds in 24 hours);

  • a light-headed feeling, like you might pass out;

  • low white blood cell counts--fever, mouth sores, skin sores, sore throat, cough, trouble breathing; or

  • low red blood cells (anemia)--pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet.

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common side effects may include:

  • nausea, diarrhea;

  • anemia;

  • feeling weak or tired;

  • hair loss;

  • rash; or

  • numbness, tingling, or burning pain in your hands or feet.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

For Healthcare Professionals

Applies to hyaluronidase / pertuzumab / trastuzumab: subcutaneous solution


Very common (10% or more): Hemoglobin low (90%), absolute lymphocytes low (89%), leukocyte count low (82%), neutrophils low (68%), anemia (36%), platelets low (27%), neutropenia (22%)

Common (1% to 10%): Leukopenia, febrile neutropenia[Ref]


Common (1% to 10%): Hypersensitivity[Ref]


Common (1% to 10%): Influenza-like illness[Ref]


Very common (10% or more): Radiation skin injury (19%), injection site reaction (15%), procedural pain (13%)

Common (1% to 10%): Injection site pain[Ref]


Very common (10% or more): Myalgia (25%), arthralgia (24%), pack pain (10%)

Common (1% to 10%): Bone pain, pain in extremity, muscle spasms, musculoskeletal pain[Ref]


Common (1% to 10%): Lacrimation increased, dry eye[Ref]


Very common (10% or more): Decreased appetite (17%), potassium low (17%), albumin low (16%), potassium high (13%), sodium low (13%), weight loss (11%)

Common (1% to 10%): Hypokalemia, glucose low, sodium high[Ref]


Very common (10% or more): Insomnia (17%)[Ref]


Common (1% to 10%): Urinary tract infection[Ref]


Very common (10% or more): Alanine aminotransferase high (58%), aspartate aminotransferase high (50%)

Common (1% to 10%): Bilirubin high


Very common (10% or more): Cough (15%), epistaxis (12%), upper respiratory infection (11%), dyspnea (10%)

Common (1% to 10%): Rhinorrhea, nasopharyngitis, paronychia

Frequency not reported: Dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency/hypoxia, acute respiratory distress syndrome, pulmonary fibrosis, exacerbation of chemotherapy-induced neutropenia[Ref]


Very common (10% or more): Asthenia (31%), fatigue (29%), pyrexia (13%)

Common (1% to 10%): Edema peripheral, malaise

Frequency not reported: Embryofetal toxicity[Ref]

Nervous system

Very common (10% or more): Dysgeusia (17%), headache (17%), peripheral sensory neuropathy (16%), peripheral neuropathy (12%), dizziness (13%), paresthesia (10%)[Ref]


Very common (10% or more): Creatinine high (84%)[Ref]


Very common (10% or more): Hot flush (12%), left ventricular cardiac dysfunction (LVEF)

Common (1% to 10%): Ejection fraction decreased

Frequency not reported: Hypertension, arrhythmias, left ventricular cardiac dysfunction, disabling cardiac failure, cardiomyopathy, cardiac death[Ref]


Very common (10% or more): Alopecia (77%), rash (16%), dry skin (15%)

Common (1% to 10%): Nail discoloration, erythema, dermatitis, nail disorder, palmar-plantar erythrodysesthesia syndrome

Uncommon (0.1% to 1%): Pruritus[Ref]


Very common (10% or more): Nausea (60%), diarrhea (60%), stomatitis (25%), constipation (22%), vomiting (20%), mucosal inflammation (15%), dyspepsia (14%)

Common (1% to 10%): Hemorrhoids, abdominal pain, abdominal pain upper[Ref]


1. "Product Information. Phesgo (hyaluronidase / pertuzumab / trastuzumab)." Genentech, South San Francisco, CA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.